Pathophysiological mechanisms of lower limb chronic venous insufficiency and possibility of its correction with Antistax
Abstract
Symptoms of lower limb chronic venous insufficiency (CVI) are related to hypertension in vena cava inferior system. All changes that take place in macrocirculatory segment of hemodynamics are reflected at microcirculatory level, including metabolic and trophic processes -- the most important function of microcirculation, which is named "transcapillary exchange". Endothelial dysfunction and blood-venous wall interface changes play a crucial role in the development of pathology. Drug therapy remains the main and integral part of CVI treatment. One of its aims is to protect venous wall, normalize permeability and alleviate CVI symptoms at microcirculatory level. Antistax efficiency in patients with CVI was demonstrated in several trials and warranted the inclusion of this drug into complex treatment of lower limb CVI.
Read the paper
Related studies
- Quercetin Influences Quorum Sensing in Food Borne Bacteria: In-Vitro and In-Silico Evidence
- Phenolic-protein interactions: insight from in-silico analyses – a review
- In Silico Discovery of Candidate Drugs against Covid-19
- Neuropharmacological Effects of Quercetin: A Literature-Based Review
- In vitro and in silico anti-dengue activity of compounds obtained from Psidium guajava through bioprospecting
- Effect of Quercetin Rich Onion Extracts on Bacterial Quorum Sensing
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.